The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CT and PET radiomic features associated with major pathologic response to neoadjuvant immunotherapy in early-stage non-small cell lung cancer (NSCLC).
 
Erica C. Nakajima
No Relationships to Disclose
 
Jeffrey P. Leal
No Relationships to Disclose
 
Wei Fu
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Jamie E. Chaft
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst)
 
Matthew David Hellmann
Stock and Other Ownership Interests - Immunai; Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Martin Pomper
Employment - Johns Hopkins University
Leadership - Cancer Targeting Systems
Stock and Other Ownership Interests - Cancer Targeting Systems
Consulting or Advisory Role - Cancer Targeting Systems
Research Funding - Cancer Targeting Systems; Progenics
Patents, Royalties, Other Intellectual Property - FutureChem USA; Neuraly (Inst); Patents licensed to Cancer Targeting Systems, Progenics Phama and Advanced Accelerator Applications (Inst); Precision Molecular (Inst); Theraly (Inst)
 
Patrick M. Forde
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Janssen
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst)